Aldeyra Therapeutics, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Aldeyra Therapeutics received notice of failure to satisfy continued listing standards. The 8-K Item 3.01 filing indicates delisting proceedings, but the specific non-compliance criterion, timeline for remediation, and exchange name are not disclosed in the provided filing text excerpt.
Why this rating
Delisting is business-changing for a ~$232M public company; threatens equity financing, investor confidence, and operational viability.
Extracted items
Tradability signal
NO TRADE
No trade: only ~$35k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.69 ▲ 0.00% | at our read · unknown $0.69 | +10 min · unknown $0.68 ▼ 2.71% | +30 min · unknown $0.69 ▼ 0.68% | +1 hr · unknown $0.69 ▼ 1.10% | +4 hrs · unknown $0.68 ▼ 2.57% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.